REGENXBIO Inc.
NASDAQ:RGNXBiotechnology
Healthcare
$7.26 +1.97%
+$0.16 today
- Market cap
- $480.05M
- Beta
- 1.03
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$5.53
52W Low $5.46High $16.19
Volume 0.70M
Average 1.24M
Balance Sheet
Inspect the capital base behind the business.
Assets
$453.03M
FY 2025 · Annual
-2.8% YoYLiabilities
$350.30M
FY 2025 · Annual
+69.8% YoYEquity
$102.73M
FY 2025 · Annual
-60.4% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 345.21M | 96.95M | 34.52M | 57.53M | 34.47M |
| Short-term Investments | 112.23M | 267.69M | 240.74M | 177.16M | 195.6M |
| Net Receivables | 32.44M | 30.29M | 26.34M | 21.57M | 27.38M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 10.2M | 7.14M | 18.85M | 12.68M | 11.9M |
| Total Current Assets | 518.83M | 415.98M | 334.97M | 278M | 281.28M |
| Property, Plant & Equipment (Net) | 192.45M | 206.8M | 192.59M | 171.31M | 152.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 391.91M | 200.56M | 38.87M | 10.18M | 15.13M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 10.72M | 9.93M | 7.54M | 6.5M | 4.61M |
| Total Non-current Assets | 595.08M | 417.29M | 239M | 187.99M | 171.75M |
| Total Assets | 1.11B | 833.27M | 573.97M | 465.99M | 453.03M |
| Account Payables | 11.39M | 27.21M | 22.79M | 22.8M | 21.36M |
| Short-term Debt | 0 | 0 | 0 | 0 | 47.9M |
| Tax Payables | 11.33M | 0 | 0 | 0 | 0 |
| Deferred Revenue | 3.33M | 1.83M | 148K | 115K | 10.45M |
| Other Current Liabilities | 57.74M | 66.67M | 86.04M | 51.92M | 20.97M |
| Total Current Liabilities | 130.47M | 130.43M | 130.27M | 103.19M | 118.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 147.41M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 18.94M |
| Other Non-current Liabilities | 134.21M | 97.84M | 49.73M | 29.01M | 638K |
| Total Non-current Liabilities | 219.13M | 186.64M | 131.96M | 103.14M | 232.2M |
| Total Liabilities | 349.61M | 317.07M | 262.23M | 206.34M | 350.3M |
| Common Stock | 4K | 4K | 4K | 5K | 5K |
| Retained Earnings | (161.23M) | (441.55M) | (705.05M) | (932.15M) | (1.13B) |
| Accumulated OCI | (2.57M) | (15.4M) | (4.43M) | (741K) | (687K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 764.3M | 516.2M | 311.74M | 259.65M | 102.73M |
| Total Debt | 86.68M | 94.8M | 89.29M | 82.03M | 260.52M |
| Net Debt | (258.53M) | (2.15M) | 54.77M | 24.51M | 226.05M |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $15.2M |
| Short-term Investments | $135.3M |
| Receivables | $10.9M |
| Other Current | $25.1M |
| Total Current Assets | $186.5M |
| PP&E (Net) | $147.4M |
| Long-term Investments | $2.5M |
| Other Non-current | $5.5M |
| Total Non-current Assets | $155.4M |
| Total Assets | $341.9M |
Analysis
Selected assets total $341.9M for Latest. The largest visible component is PP&E (Net) at $147.4M, about 43.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
How much cash does RGNX have?
REGENXBIO Inc. (RGNX) reported $34.47M in cash and equivalents in fiscal 2025.
How much debt does RGNX carry?
REGENXBIO Inc. (RGNX) reported $260.52M of total debt, with net debt of $226.05M.
Continue the stock analysis
Jump to another research area for this company.